New Medical Therapies™

Tardive Dyskinesia

April 11, 2011

Neurocrine Biosciences reported interim results from a phase IIa trial of NBI-98854 for Tardive Dyskinesia. This Canadian-based, open label, dose escalation trial plans to enroll up to ten subjects with schizophrenia and moderate to severe Tardive Dyskinesia. Data are from six subjects in the initial cohort. The subjects received three, four-day periods of NBI-98854 at increasing doses of 12.5mg, 25mg and 50mg administered once daily. After discontinuation of NBI-98854, a seven-day washout period was followed by a final assessment. The impact of NBI-98854 on the dyskinesia was assessed utilizing the Abnormal Involuntary Movement Scale (AIMS). In this initial cohort of six subjects, the mean baseline score was 14.3. After the twelve days of dosing, the mean AIMS score decreased to 8.4, a reduction of 41.3%. Reduction in abnormal involuntary movements was shown across multiple assessment points. After the seven-day washout period most of the AIMS scores returned to baseline levels.